Daptomycin and Dasatinib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Daptomycin (daptomycin) and Dasatinib (dasatinib). Common drug interactions include wound dehiscence among females and nephropathy toxic among males.

The phase IV clinical study analyzes what interactions people have when they take Daptomycin and Dasatinib. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Daptomycin?

Daptomycin has active ingredients of daptomycin. eHealthMe is studying from 7,879 Daptomycin users. Check the latest studies of Daptomycin.

What is Dasatinib?

Dasatinib has active ingredients of dasatinib. eHealthMe is studying from 9,407 Dasatinib users. Check the latest studies of Dasatinib.



On Mar, 08, 2026

11 people who take Daptomycin and Dasatinib together, and have interactions are studied.

Daptomycin and Dasatinib drug interactions.

What are the common drug interactions of Daptomycin and Dasatinib, by gender? *:

female:

  1. Wound dehiscence (a surgical incision reopens either internally or externally)
  2. Escherichia infection (bacterial infection by escherichia coli)
  3. Febrile neutropenia (fever with reduced white blood cells)
  4. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  5. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  6. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  7. Osteomyelitis (infection of bone)
  8. Staphylococcal infection (an infection with staphylococcus bacteria)
  9. Impaired healing
  10. Infection

male:

  1. Nephropathy toxic (damage to kidney due to toxins)
  2. Confusional state
  3. Delirium (wild excitement)
  4. Pulmonary oedema (fluid accumulation in the lungs)

What are the common drug interactions of Daptomycin and Dasatinib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  2. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Nephropathy toxic (damage to kidney due to toxins)
  2. Escherichia infection (bacterial infection by escherichia coli)
  3. Febrile neutropenia (fever with reduced white blood cells)
  4. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
  5. Osteomyelitis (infection of bone)
  6. Staphylococcal infection (an infection with staphylococcus bacteria)
  7. Impaired healing
  8. Infection
  9. Neutropenia (an abnormally low number of neutrophils)
  10. Postoperative wound infection

60+:

  1. Confusional state
  2. Delirium (wild excitement)
  3. Pulmonary oedema (fluid accumulation in the lungs)

What are the existing conditions these people have? *

  1. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 54.55%
  2. Staphylococcal Infection (an infection with staphylococcus bacteria): 3 people, 27.27%
  3. Neutropenic Sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection): 3 people, 27.27%
  4. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 3 people, 27.27%
  5. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 18.18%
  6. Postoperative Wound Infection: 1 person, 9.09%
  7. Oral Candidiasis (fungal infection of mouth): 1 person, 9.09%
  8. Neutropenic Colitis (inflammation of the cecum, often with involvement of the ascending colon and ileum, a life threatening condition): 1 person, 9.09%
  9. Infection: 1 person, 9.09%
  10. Immunodeficiency Disorders: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Daptomycin and Dasatinib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Daptomycin and Dasatinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Daptomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Dasatinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Daptomycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dasatinib and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on daptomycin and dasatinib (the active ingredients of Daptomycin and Dasatinib, respectively), and Daptomycin and Dasatinib (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: